T2 Biosystems, Inc. (TTOO)

3.7200 +0.0700 (+1.92%) 收市：04:00PM EDT

T2 Biosystems, Inc.

101 Hartwell Avenue
Lexington, MA 02421
United States
781 761 4646
https://www.t2biosystems.com

版塊: Healthcare
行業: Diagnostics & Research
全職員工: 113

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. John J. Sperzel III, B.Sc.	President, CEO & Chairman	865.5k	無	1963
Mr. Michael Terrence Gibbs Esq.	Senior VP, General Counsel & Company Secretary	622.6k	無	1971
Ms. Kelley J. Morgan	Chief People Officer	無	無	1976
Mr. Brett A. Giffin	Chief Commercial Officer	無	無	1959
Dr. Roger Smith Ph.D.	Senior Vice President of Science Research & Development	無	無	1965

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood molecular diagnostic test panel that detects lethal form of common blood stream infections, which cause sepsis and candidemia; T2Bacteria panel, a direct-from-blood molecular diagnostic test panel, which detects bacterial pathogens in blood stream infections; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2Biothreat, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument and detects biothreat pathogens. In addition, it is developing T2Cauris panel, a direct-from-blood molecular diagnostic test that runs on the T2Dx Instrument and detects Candida auris; and T2Lyme panel, a direct-from-blood molecular diagnostic test panel that runs on the T2Dx Instrument to identify the bacteria that cause Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

公司管治

截至 無 止，T2 Biosystems, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。